MYO7B

Across TCGA pan-cancer cohorts, MYO7B RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MYO7B data layer compared with 12 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher MYO7B RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MYO7B expression acts as an unfavorable survival marker, although some lineages such as UVM and SCLC show a favorable association.

UVM, MESO, and SCLC are the cancer types where MYO7B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	All	0.810	0.254	<.001	115	view →
MESO	OS	Median	All	0.420	0.660	<.001	92	view →
SCLC	OS	Tertile	All	0.642	0.250	.001	54	view →
LUSC	DFS	Median	III,IV	0.204	0.904	<.001	41	view →
KIRC	OS	Median	All	0.700	0.559	<.001	40	view →
DLBC	DFS	Median	All	0.600	0.964	.002	40	view →
KIRP	DFS	Median	IV	0.622	0.040	.006	40	view →
SARC	DFS	Median	All	0.612	0.410	<.001	38	view →
UCEC	OS	Tertile	All	0.549	0.844	<.001	36	view →
ESCA	OS	Tertile	All	0.427	1.000	.007	33	view →
THCA	DFS	Tertile	IV	1.000	0.708	.008	14	view →
LUAD	DFS	Median	IV	0.666	0.978	.015	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

MYO7B–UVM (DFS)

Open the UVM breakdown →